348 related articles for article (PubMed ID: 1689220)
1. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
[TBL] [Abstract][Full Text] [Related]
2. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow.
Keever CA; Welte K; Small T; Levick J; Sullivan M; Hauch M; Evans RL; O'Reilly RJ
Blood; 1987 Dec; 70(6):1893-903. PubMed ID: 3118990
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer (LAK) cells. VI. NK1.1+, CD3+ LAK effectors are derived from CD4-, CD8-, NK1.1- precursors.
Ballas ZK; Rasmussen W
Cell Immunol; 1991 May; 134(2):296-313. PubMed ID: 1827045
[TBL] [Abstract][Full Text] [Related]
5. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
Roussel E; Gerrard JM; Greenberg AH
Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
[TBL] [Abstract][Full Text] [Related]
6. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
Miller JS; Verfaillie C; McGlave P
Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
8. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
[TBL] [Abstract][Full Text] [Related]
9. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
10. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
[TBL] [Abstract][Full Text] [Related]
11. Immunomagnetic isolation of NK and LAK cells.
Naume B; Nonstad U; Steinkjer B; Funderud S; Smeland E; Espevik T
J Immunol Methods; 1991 Jan; 136(1):1-9. PubMed ID: 1704900
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.
Anderson PM; Bach FH; Ochoa AC
Cancer Immunol Immunother; 1988; 27(1):82-8. PubMed ID: 3260824
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
14. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
Whiteside TL; Wang YL; Selker RG; Herberman RB
Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis.
Kantor TV; Whiteside TL; Friberg D; Buckingham RB; Medsger TA
Arthritis Rheum; 1992 Jun; 35(6):694-9. PubMed ID: 1376124
[TBL] [Abstract][Full Text] [Related]
17. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic.
Vujanovic NL; Rabinowich H; Lee YJ; Jost L; Herberman RB; Whiteside TL
Cell Immunol; 1993 Oct; 151(1):133-57. PubMed ID: 8402925
[TBL] [Abstract][Full Text] [Related]
18. Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow.
Drobyski WR; Piaskowski V; Ash RC; Casper JT; Truitt RL
Transplantation; 1990 Oct; 50(4):625-32. PubMed ID: 1699309
[TBL] [Abstract][Full Text] [Related]
19. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
Yarbrough WC; Weissler JC
Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
[TBL] [Abstract][Full Text] [Related]
20. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
Drobyski WR; LeFever AV; Truitt RL
Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
